The Australian Clinical Practice Guideline for ADHD: A Summary for Clinicians
The Australian Clinical Practice Guideline for ADHD is a comprehensive guide to diagnosing, treating and managing ADHD.
This guideline provides evidence-based best practice recommendations for the assessment, diagnosis, and management of ADHD in children and adolescents. It also provides guidance for health professionals on managing the long-term effects of ADHD and offering support for those affected.
The Psych Scene Hub has summarised the main points of the Australian Clinical Practice Guideline for ADHD, so that readers can quickly and easily understand the key points of the guideline.
This summary will provide an overview of the most important aspects of the guideline and will be useful for those looking for more information on the diagnosis and treatment of ADHD.
The prevalence of adult ADHD in Australia is between 2% and 6% (similar to international prevalence)
The social and economic costs of ADHD are estimated at $20.42 billion per year or $25,071 per individual with ADHD per annum. [Deloitte Access Economics. (2019). The social and economic costs of ADHD in Australia. Retrieved from Canberra]
This article summarises the key recommendations from the Australian Evidence-Based Clinical Practice Guidelines for Attention Deficit Hyperactivity Disorder (ADHD). [AADPA]
This summary is best read in combination with other articles we have previously covered for a comprehensive overview of ADHD.
Simonoff, E., Taylor, E., Baird, G., Bernard, S., Chadwick, O., Liang, H., … & Jichi, F. (2013). Randomized controlled double‐blind trial of optimal dose methylphenidate in children and adolescents with severe attention deficit hyperactivity disorder and intellectual disability. Journal of Child Psychology and Psychiatry, 54(5), 527-535.